Thrombosis and Haemostasis, Table of Contents Thromb Haemost 2005; 93(01): 165-171DOI: 10.1160/TH04-04-0402 New Technologies and Diagnostic Tools Schattauer GmbH Plasma glycocalicin as a source of GPIbα in the von Willebrand factor ristocetin cofactor ELISA Authors Author Affiliations Karen Vanhoorelbeke 3 Laboratory for Thrombosis Research, IRC, KU Leuven Campus Kortrijk, Kortrijk, Belgium Inge Pareyn 3 Laboratory for Thrombosis Research, IRC, KU Leuven Campus Kortrijk, Kortrijk, Belgium Agota Schlammadinger 1 2nd Department of Medicine, University of Debrecen, Debrecen, Hungary Stephan Vauteri 3 Laboratory for Thrombosis Research, IRC, KU Leuven Campus Kortrijk, Kortrijk, Belgium Marc F. Hoylaerts 2 Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium Jef Arnout 2 Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium Hans Deckmyn 3 Laboratory for Thrombosis Research, IRC, KU Leuven Campus Kortrijk, Kortrijk, Belgium Recommend Article Abstract Full Text PDF Download(opens in new window) Keywords KeywordsPlasma glycocalicin - von Willebrand disease (VWD) - von Willebrand ristocetin cofactor activity (VWF:RCo) assay References References 1 Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520-25. 2 Ewenstein BM. Von Willebrand's disease. Annu Rev Med 1997; 48: 525-42. 3 Castaman G, Federici AB, Rodeghiero F. et al von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88: 94-108. 4 Hoylaerts MF, Nuyts K, Peerlinck K. et al Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin. Biochem J 1995; 306 Pt (02) 453-463. 5 Howard MA, Firkin BG. Ristocetin--a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-9. 6 Federici AB, Bader R, Pagani S. et al Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. Br J Haematol 1989; 73: 93-9. 7 Macfarlane DE, Stibbe J, Kirby EP. et al Letter: A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-8. 8 Brinkhous KM, Graham JE, Cooper HA. et al Assay of von Willebrand factor in von Willebrand's disease and hemophilia: use of a macroscopic platelet aggregation test. Thromb Res 1975; 6: 267-72. 9 Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. Pathology 1997; 29: 385-91. 10 Vanhoorelbeke K, Cauwenberghs N, Vauterin S. et al A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83: 107-13. 11 Vanhoorelbeke K, Cauwenberghs N, Vandecasteele G. et al Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease. Semin Thromb Hemost 2002; 28: 161-6. 12 Okumura T, Jamieson GA. Platelet glycocalicin: a single receptor for platelet aggregation induced by thrombin or ristocetin. Thromb Res 1976; 8: 701-6. 13 Yamamoto K, Kosaki G, Suzuki K. et al Cleavage site of calcium-dependent protease in human platelet membrane glycoprotein Ib. Thromb Res 1986; 43: 41-55. 14 McGowan EB, Yeo KT, Detwiler TC. The action of calcium-dependent protease on platelet surface glycoproteins. Arch Biochem Biophys 1983; 227: 287-301. 15 Wicki AN, Clemetson KJ. Structure and function of platelet membrane Glycoprotein-Ib and Glycoprotein- V – effects of leukocyte elastase and other proteases on platelets response to Von Willebrand-Factor and Thrombin. Eur J Biochem 1985; 153: 1-11. 16 Bergmeier W, Burger PC, Piffath CL. et al Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood 2003; 102: 4229-35. 17 Coller BS, Kalomiris E, Steinberg M. et al Evidence that glycocalicin circulates in normal plasma. J Clin Invest 1984; 73: 794-9. 18 Beer JH, Buchi L, Steiner B. Glycocalicin: a new assay--the normal plasma levels and its potential usefulness in selected diseases. Blood 1994; 83: 691-702. 19 Steinberg MH, Kelton JG, Coller BS. Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders. N Engl J Med 1987; 317: 1037-42. 20 van den Oudenrijn S, Bruin M, Folman CC. et al Three parameters, plasma thrombopoietin levels, plasma glycocalicin levels and megakaryocyte culture, distinguish between different causes of congenital thrombocytopenia. Br J Haematol 2002; 117: 390-8. 21 Cauwenberghs N, Ajzenberg N, Vauterin S. et al Characterization of murine anti-glycoprotein Ib monoclonal antibodies that differentiate between shear-induced and ristocetin/botrocetin- induced glycoprotein Ib-von Willebrand factor interaction. Haemostasis 2000; 30: 139-48. 22 Cauwenberghs N, Vanhoorelbeke K, Vauterin S. et al Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood 2001; 98: 652-60. 23 Loscalzo J, Handin I R. Platelet glycocalicin. Methods Enzymol 1992; 215: 289-94. 24 Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-21. 25 Federici AB, Canciani MT, Forza I. et al A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ib alpha for the diagnosis of patients with low von Willebrand factor levels. Haematologica 2004; 89: 77-85.
